[HTML][HTML] A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: the NVALT-10 …
JG Aerts, H Codrington, NAG Lankheet, S Burgers… - Annals of oncology, 2013 - Elsevier
Background Epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) administered
concurrently with chemotherapy did not improve outcome in non-small-cell lung cancer …
concurrently with chemotherapy did not improve outcome in non-small-cell lung cancer …
A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: the NVALT-10 study …
JG Aerts, H Codrington, NAG Lankheet… - Annals of …, 2013 - cris.maastrichtuniversity.nl
Epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) administered concurrently
with chemotherapy did not improve outcome in non-small-cell lung cancer (NSCLC) …
with chemotherapy did not improve outcome in non-small-cell lung cancer (NSCLC) …
[PDF][PDF] A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: the NVALT-10 …
JG Aerts, H Codrington, NAG Lankheet… - Annals of …, 2013 - researchgate.net
Background: Epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) administered
concurrently with chemotherapy did not improve outcome in non-small-cell lung cancer …
concurrently with chemotherapy did not improve outcome in non-small-cell lung cancer …
A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: the NVALT-10 study …
JG Aerts, H Codrington, NAG Lankheet… - Annals of …, 2013 - research.rug.nl
Epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) administered concurrently
with chemotherapy did not improve outcome in non-small-cell lung cancer (NSCLC) …
with chemotherapy did not improve outcome in non-small-cell lung cancer (NSCLC) …
A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: The NVALT-10 study
JG Aerts, H Codrington, NAG Lankheet… - Annals of …, 2013 - research.sahmri.org.au
Background: Epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) administered
concurrently with chemotherapy did not improve outcome in non-small-cell lung cancer …
concurrently with chemotherapy did not improve outcome in non-small-cell lung cancer …
[HTML][HTML] A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: the NVALT-10 …
JG Aerts, H Codrington, NAG Lankheet… - Annals of …, 2013 - annalsofoncology.org
Background Epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) administered
concurrently with chemotherapy did not improve outcome in non-small-cell lung cancer …
concurrently with chemotherapy did not improve outcome in non-small-cell lung cancer …
[PDF][PDF] A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: the NVALT-10 …
JG Aerts, H Codrington, NAG Lankheet, S Burgers… - Annals of …, 2013 - core.ac.uk
Background: Epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) administered
concurrently with chemotherapy did not improve outcome in non-small-cell lung cancer …
concurrently with chemotherapy did not improve outcome in non-small-cell lung cancer …
A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: the NVALT-10 study.
JG Aerts, H Codrington, NA Lankheet… - Annals of Oncology …, 2013 - europepmc.org
Background Epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) administered
concurrently with chemotherapy did not improve outcome in non-small-cell lung cancer …
concurrently with chemotherapy did not improve outcome in non-small-cell lung cancer …
A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: the NVALT-10 study
JG Aerts, H Codrington… - Annals of oncology …, 2013 - pubmed.ncbi.nlm.nih.gov
Background Epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) administered
concurrently with chemotherapy did not improve outcome in non-small-cell lung cancer …
concurrently with chemotherapy did not improve outcome in non-small-cell lung cancer …
[PDF][PDF] A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: the NVALT-10 …
JG Aerts, H Codrington, N Lankheet, S Burgers… - 2013 - repository.ubn.ru.nl
BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitors (TKIs)
administered concurrently with chemotherapy did not improve outcome in non-small-cell …
administered concurrently with chemotherapy did not improve outcome in non-small-cell …